Empagliflozin vs Ipilimumab

## Empagliflozin vs Ipilimumab: Overview

This comparison examines the pharmacological differences between **Empagliflozin** and **Ipilimumab**.

## Mechanism of Action

**Empagliflozin**: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Empagliflozin — 12.4 hours; Ipilimumab — 14.7 days.

## Chemical Properties

**Molecular Formula**: Empagliflozin — C23H27ClO7; Ipilimumab — N/A.

**Molecular Weight**: Empagliflozin — 450.9100 g/mol; Ipilimumab — N/A.

**Type**: Empagliflozin — Small molecule; Ipilimumab — Antibody.